AGIOS PHARMACEUTICALS - ONCOLOGY BUSINESS
Agios Pharmaceuticals is a biopharmaceutical company that discovers and develops therapeutics in the field of cancer metabolism. Metabolic immuno-oncology aims to modulate the activity of relevant immune cells by targeting critical metabolic enzymes, thereby enhancing the immune-mediated anti-tumor response.
AGIOS PHARMACEUTICALS - ONCOLOGY BUSINESS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Address:
Cambridge, Massachusetts, United States
Country:
United States
Status:
Active
Similar Organizations
Fovea Pharmaceuticals
Fovea Pharmaceuticals is a French biopharmaceutical company that discovers and develops drugs for the treatment of ocular diseases.
More informations about "Agios Pharmaceuticals - Oncology business"
Servier to Acquire Agios Pharmaceuticals’ Oncology Business
Company, today announced that it has entered into an agreement for the acquisition of Agios Pharmaceuticals’ oncology business including its commercial, clinical and research-stage …See details»
Servier Completes Acquisition of Agios Pharmaceuticals’ Oncology …
As part of the transaction, U.S.-based Agios employees who primarily support the oncology business will join Servier Pharmaceuticals LLC, a U.S. subsidiary of Servier. The transaction …See details»
Servier completes acquisition of Agios’ oncology …
On April 1 st , 2021, Servier announced the successful acquisition of Agios Pharmaceuticals’ commercial, clinical, and research-stage oncology portfolio.This acquisition immediately strengthens Servier’s commercial presence in the …See details»
Agios Pharmaceuticals - Crunchbase Company Profile …
Agios Pharmaceuticals is a biopharmaceutical company, discovers and develops therapeutics in the field of cancer metabolism. It also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The company's …See details»
Agios
Dec 6, 2024 Over the 12+ years Agios has been in existence, we have remained committed to patients first and to following the science. Our legacy is rooted in a powerful set of strengths, …See details»
About Us - Agios
Agios was founded in 2008 to unlock a new field of discovery in cellular metabolism. This singular focus on metabolic disease has taken us from the development of precision therapies in oncology to pioneering new …See details»
Servier to Acquire Agios Pharmaceuticals’ Oncology Business
PARIS and BOSTON, Dec. 21, 2020 /PRNewswire/ – Servier, a global pharmaceutical company, today announced that it has entered into an agreement for the acquisition of Agios …See details»
Agios Pharmaceuticals - Wikipedia
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for …See details»
Servier Completes Acquisition of Agios …
PARIS and BOSTON, April 1, 2021 /PRNewswire/ -- Servier, a global pharmaceutical company, today announced that it has successfully completed its acquisition of Agios Pharmaceuticals' commercial ...See details»
History - Agios
Royalty Pharma acquired rights to IDHIFA® worldwide net sales and outstanding regulatory milestone payments for $255 million. ... Announced agreement to sell oncology business to Servier for up to $2 billion plus royalties, enabling new …See details»
Agios Announces Closing of Oncology Business Sale to Servier
Apr 1, 2021 In consideration for its oncology portfolio, Agios received from Servier $1.8 billion in upfront cash and is eligible to receive an additional $200 million in a potential future milestone …See details»
Agios Announces Closing of Oncology Business Sale to
Jan 4, 2021 As previously disclosed, the Agios board of directors authorized the company to repurchase up to $1.2 billion of its outstanding shares, using the proceeds from the sale of the …See details»
Agios Shareholders Approve Sale of Oncology Business to Servier
CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined …See details»
Agios Exits Oncology | Cancer Discovery | American Association for ...
Mar 2, 2021 The company behind the only two IDH-targeted drugs on the market has exited the cancer field. Late last year, Agios Pharmaceuticals, maker of the IDH1 inhibitor ivosidenib …See details»
Agios Exits Oncology - PubMed
Agios Pharmaceuticals, the company behind the only two IDH-targeted drugs on the market and a brain-penetrant IDH inhibitor in late-stage testing for glioma, announced plans to sell its …See details»
Servier to Acquire Agios Pharmaceuticals’ Oncology Business
PARIS and BOSTON, Dec. 21, 2020 /PRNewswire/ -- Servier, a global pharmaceutical company, today announced that it has entered into an agreement for the acquisition of Agios …See details»
Agios Pharmaceuticals (Oncology Business) - PitchBook
Information on acquisition, funding, investors, and executives for Agios Pharmaceuticals (Oncology Business). Use the PitchBook Platform to explore the full profile.See details»
Servier to Acquire Agios Pharmaceuticals' Oncology Business - PR …
Dec 21, 2020 Servier to Acquire Agios Pharmaceuticals' Oncology Business - Transaction includes commercial, clinical and research-stage oncology portfolio and employees for up to …See details»
Agios Pharmaceuticals - Oncology Business - Products, …
Agios Pharmaceuticals - Oncology Business is a biopharmaceutical company dedicated to the discovery and development of therapeutics in the field of cancer metabolism. To support and …See details»
Servier Completes Acquisition of Agios Pharmaceuticals’ Oncology …
PARIS and BOSTON, April 1, 2021 /PRNewswire/ --Servier a global pharmaceutical company, today announced that it has successfully completed its acquisition of Agios Pharmaceuticals, …See details»